References

Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the Comparison of Age-Related Macular Degeneration Treatments Trials

10.1097/iae.0000000000000483 · 2015 · External reference

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

10.1136/bjophthalmol-2014-305702 · 2014 · External reference

The Royal College of Ophthalmologists guidelines on AMD: executive summary

10.1038/eye.2013.233 · 2013 · External reference

Unresolved reference

2018 · External reference

Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration

10.1038/s41433-020-0799-y · 2020 · External reference

The patients’ view: age-related macular degeneration and its effects—a meta-synthesis

2020 · External reference

Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration

10.1080/13548506.2016.1274040 · 2018 · External reference

Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study

10.1016/j.ajo.2015.06.023 · 2015 · External reference

Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration

10.1371/journal.pone.0129361 · 2015 · External reference

Unresolved reference

2020 · External reference

Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review

10.1016/j.ophtha.2020.07.060 · 2021 · External reference

Management of neovascular age-related macular degeneration during the COVID-19 pandemic

10.1016/j.oret.2020.05.015 · 2020 · External reference

Factors associated with COVID-19-related death using OpenSAFELY

10.1038/s41586-020-2521-4 · 2020 · External reference

Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration

10.1016/j.ajo.2020.12.012 · 2021 · External reference

Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration

10.3390/pharmaceutics11080365 · 2019 · External reference

Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

2020 · External reference

The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis

10.1016/j.ajo.2018.05.026 · 2018 · External reference

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

10.1016/j.ajo.2009.01.024 · 2009 · External reference

Ranibizumab according to need: a treatment for age-related macular degeneration

10.1016/j.ajo.2007.02.024 · 2007 · External reference

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

10.1016/j.ophtha.2012.03.053 · 2012 · External reference

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

10.1016/s0140-6736(13)61501-9 · 2013 · External reference

A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab

10.1038/eye.2017.67 · 2017 · External reference

Nonresponders to ranibizumab anti-VEGF treatment are actually short-term responders: a prospective spectral-domain OCT study

10.1016/j.oret.2019.11.004 · 2020 · External reference

Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors

10.1016/j.preteyeres.2017.12.002 · 2018 · External reference

Baseline visual acuity at wet AMD diagnosis predicts long-term vision outcomes: an analysis of the IRIS Registry

10.3928/23258160-20201104-05 · 2020 · External reference

10.1016/j.oret.2020.11.004

10.1016/j.oret.2020.11.004 · External reference

Novel long-acting pharmacotherapy for exudative age related macular degeneration

10.2174/1381612825666190123165216 · 2018 · External reference

Innovative therapies for neovascular age-related macular degeneration

10.1080/14656566.2019.1636031 · 2019 · External reference

Evaluation of a self-imaging SD-OCT system for remote monitoring of patients with neovascular age related macular degeneration

10.1055/a-1271-6834 · 2020 · External reference

Unresolved reference

External reference

Retinal specialist vs artificial intelligence detection of retinal fluid from optical coherence tomography: AREDS2 10-year follow-on

10.1016/j.ophtha.2020.06.038 · 2021 · External reference

Automated identification of lesion activity in neovascular age-related macular degeneration

10.1016/j.ophtha.2016.04.005 · 2016 · External reference

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD

10.1038/s41433-020-01354-4 · 2021 · External reference

Unresolved reference

External reference

Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results

10.1016/j.ophtha.2018.11.025 · 2019 · External reference

Self-examination low-cost full-field OCT (SELFF-OCT) for patients with various macular diseases

10.1007/s00417-020-05035-6 · 2021 · External reference

Safety and feasibility of a novel sparse optical coherence tomography device for patient-delivered retina home monitoring

10.1167/tvst.7.4.8 · 2018 · External reference

Optical coherence tomography in the 2020s-outside the eye clinic

10.1038/s41433-020-01263-6 · 2021 · External reference